Why should Eliquis (apixaban) be restarted for deep vein thrombosis (DVT) prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Why Restart Eliquis for DVT Prevention

Eliquis (apixaban) should be restarted after procedures or interruptions because discontinuing anticoagulation leaves patients vulnerable to recurrent venous thromboembolism (VTE), which carries significant morbidity and mortality risk, while apixaban provides highly effective prevention with a favorable bleeding profile.

The Core Rationale for Restarting Anticoagulation

The fundamental reason to restart Eliquis centers on preventing recurrent VTE, which is the primary driver of morbidity and mortality in these patients. Here's the algorithmic approach:

Risk of Recurrence Without Anticoagulation

Indefinite treatment reduces recurrent VTE risk by approximately 90%, but anticoagulants don't eliminate future risk after discontinuation 1. The recurrence rates vary by clinical scenario:

  • Unprovoked VTE: 4.5% per year after stopping treatment 1
  • Provoked VTE (transient risk factors): 2.5% per year 1
  • Cancer-associated VTE: ~20% in first 12 months 1
  • First year after withdrawal: Up to 10% recurrence rate 1

When Recurrent VTE Occurs

In patients with prior PE, recurrence manifests as symptomatic PE more frequently than DVT, making the stakes particularly high 1. This means stopping anticoagulation in PE patients carries life-threatening risk.

Specific Scenarios for Restarting Eliquis

After Surgical/Procedural Interruption

Restart Eliquis as soon as adequate hemostasis is established 2:

  • Low bleeding risk procedures: Restart 24-48 hours post-procedure (typically 48 hours) 3
  • Moderate/high bleeding risk procedures: Restart 48-72 hours post-procedure (typically 72 hours) 3
  • Bridging is NOT required during the 24-48 hour interruption period 2

The French perioperative guidelines 4 specify that when surgical hemostasis is obtained, DOACs can be restarted at full therapeutic doses without the need for initial prophylactic dosing.

Extended/Long-term Prevention

For patients who have completed initial treatment (typically 6 months), the decision algorithm is:

1. Unprovoked VTE + Low-Moderate Bleeding Risk:

  • Continue Eliquis indefinitely at reduced dose (2.5 mg twice daily) 5, 6
  • This provides 90% reduction in recurrent VTE 1
  • Reduced-dose apixaban (2.5 mg BID) after 6 months is as effective as full-dose with lower bleeding risk 5, 7

2. Provoked VTE (transient risk factor) + Enduring Risk Factors:

  • Restart/continue Eliquis 2.5 mg twice daily for extended therapy 8
  • Recent 2025 HI-PRO trial showed 1.3% recurrence with apixaban vs 10.0% with placebo (HR 0.13,95% CI 0.04-0.36) 8
  • Major bleeding remained minimal (1 patient vs 0 in placebo) 8

3. Cancer-Associated VTE:

  • Continue anticoagulation indefinitely while cancer remains active 1, 6
  • For extended therapy beyond 6 months: Reduced-dose apixaban 2.5 mg BID is superior 7
  • API-CAT trial (2025) showed reduced-dose was noninferior for VTE prevention (2.1% vs 2.8%) but with significantly less bleeding (12.1% vs 15.6%, HR 0.75) 7

Apixaban's Specific Advantages

Apixaban offers unique benefits that justify its restart over alternatives:

Efficacy Profile

  • Noninferior to enoxaparin/warfarin for acute VTE treatment (AMPLIFY trial: 2.3% vs 2.7% recurrence) 9, 10
  • Significantly reduces recurrent VTE vs placebo in extended treatment (AMPLIFY-EXT) 1, 10
  • Reduces hospitalizations by 20% compared to warfarin (HR 0.804, P=0.045) 11

Safety Profile

  • Major bleeding 0.6% vs 1.8% with warfarin (RR 0.31, P<0.001) 9, 10
  • Lower bleeding than warfarin in extended therapy without increased VTE risk 12
  • Reduced-dose option (2.5 mg BID) after 6 months maintains efficacy with minimal bleeding 5, 7

Practical Advantages

  • No parenteral lead-in required (unlike edoxaban or dabigatran) 13
  • No routine monitoring needed 14, 15
  • Twice-daily dosing may improve compliance through routine 13
  • Predictable pharmacokinetics allow fixed dosing 14

Critical Pitfalls to Avoid

1. Don't delay restart excessively:

  • Balance hemostasis concerns against rapidly rising VTE risk
  • Use the 48-72 hour window as maximum for most procedures 3

2. Don't use prophylactic dosing initially:

  • Restart at full therapeutic dose unless specifically indicated otherwise 4
  • Exception: Post-orthopedic surgery prophylaxis uses 2.5 mg BID 2

3. Don't forget dose reduction for extended therapy:

  • After 6 months of full-dose treatment, reduce to 2.5 mg BID for indefinite prevention 5, 2, 7
  • This maintains efficacy while reducing bleeding risk

4. Caution in specific populations:

  • GI/genitourinary malignancies: Higher mucosal bleeding risk with DOACs; consider LMWH 16, 13
  • Severe renal impairment (CrCl <15 mL/min): Insufficient safety data 9, 13
  • Mechanical heart valves: Absolute contraindication for all DOACs 17

The Bottom Line

Restart Eliquis because the alternative—recurrent VTE—carries 4.5-10% annual risk with potentially fatal consequences, while apixaban provides 90% risk reduction with major bleeding rates under 1% in most populations. The 2025 evidence strongly supports reduced-dose continuation (2.5 mg BID) for extended therapy, offering optimal balance of efficacy and safety 8, 7.

References

Research

Apixaban for Extended Treatment of Provoked Venous Thromboembolism.

The New England journal of medicine, 2025

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Related Questions

I have an old deep vein thrombosis (DVT) and am on apixaban (Eliquis); a repeat Doppler ultrasound shows chronic DVT unchanged. Should I continue the same dose of apixaban?
What is the recommended dosing regimen of apixaban for treatment and prophylaxis of venous thromboembolism in adults, including adjustments for age, weight, and renal function?
Can Eliquis (apixaban) be used to treat deep‑vein thrombosis (DVT) in adults, and what is the recommended dosing and contraindications?
Is a daily dose of 5 mg of Eliquis (apixaban) effective for preventing recurrent pulmonary embolism?
Will a deep‑vein thrombosis (DVT) in the leg cause pain one week later while the patient is taking Eliquis (apixaban)?
Can a patient with an allergy to omeprazole (Prilosec) safely take pantoprazole (Protonix)?
Can a patient taking telmisartan and hydrochlorothiazide safely use a fixed‑dose combination tablet containing ibuprofen, paracetamol (acetaminophen), and caffeine for pain relief?
Can a patient who is allergic to Prilosec (omeprazole) safely take Protonix (pantoprazole) or Pepcid (famotidine)?
What is the survival rate for patients with estrogen‑receptor‑positive, progesterone‑receptor‑positive, nuclear grade 1 breast cancer with bone metastases?
How should a pregnant woman with anti‑Jkᵃ (Kidd) alloantibody be managed?
After starting intravenous N‑acetylcysteine, how long does biochemical improvement (decline in ALT/AST and bilirubin) occur in a hepatitis B virus flare with severe acute liver injury?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.